GlassScriptPhysician profile
Beth Michele Schultz
NPI 1881967255
$5,959.03
in general payments reported to CMS, 2019-2025
28 companies · $1,815 in 2025
The $1,815 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $192 · 2022: $592 · 2023: $1,542 · 2024: $1,818 · 2025: $1,815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,174.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,191.94 | 2021-2025 | Xifaxan, Trulance |
| Abbvie INC. | $1,030.26 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $522.95 | 2021-2025 | Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $463.88 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $357.30 | 2022-2025 | |
| Ardelyx, INC. | $316.12 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $241.59 | 2023-2025 | |
| Celgene Corporation | $231.48 | 2021-2024 | Zeposia |
| Dermavant Sciences, INC. | $215.66 | 2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $200.69 | 2023-2025 | Dupixent |
| Janssen Biotech, INC. | $188.60 | 2021-2025 | Stelara, Tremfya |
| Pfizer INC. | $157.58 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $138.68 | 2024-2025 | Iqirvo, Bylvay |
| Nestle Healthcare Nutrition INC. | $130.98 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $78.02 | 2024-2025 | Zenpep |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $76.05 | 2024-2025 | |
| Ironwood Pharmaceuticals, INC | $67.07 | 2023 | Linzess |
| Qol Medical, LLC | $58.69 | 2022-2025 | Sucraid |
| Braintree Laboratories, INC. | $50.98 | 2021-2023 | Sutab |
| Madrigal Pharmaceuticals | $49.54 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $40.08 | 2023 | Dificid |
| Lilly USA, LLC | $37.17 | 2024-2025 | Omvoh |
| Sandoz INC. | $26.62 | 2023 | Hyrimoz |
| Novo Nordisk INC | $22.69 | 2025 | Wegovy |
| Medtronic, INC. | $19.08 | 2025 | Synchromedii |
| Alnylam Pharmaceuticals INC. | $16.66 | 2024 | Givlaari |
| Ferring Pharmaceuticals INC. | $14.84 | 2023 | Rebyota |
| Evoke Pharma, INC. | $13.83 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.